David F. Novack Net Worth

The estimated Net Worth of David F Novack is at least 5.16 百万$ dollars as of 10 February 2024. Mr Novack owns over 8,833 units of Dynavax Technologies stock worth over 262,211$ and over the last 12 years he sold DVAX stock worth over 4,094,795$. In addition, he makes 799,198$ as Pres & COO at Dynavax Technologies.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Novack DVAX stock SEC Form 4 insiders trading

Mr has made over 30 trades of the Dynavax Technologies stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 8,833 units of DVAX stock worth 96,368$ on 10 February 2024.

The largest trade he's ever made was exercising 52,500 units of Dynavax Technologies stock on 10 February 2022 worth over 572,775$. On average, Mr trades about 12,776 units every 49 days since 2013. As of 10 February 2024 he still owns at least 24,034 units of Dynavax Technologies stock.

You can see the complete history of Mr Novack stock trades at the bottom of the page.

Mr. David F. Novack biography

David F. Novack is the Pres & COO at Dynavax Technologies.

What is the salary of Mr Novack?

As the Pres & COO of Dynavax Technologies, the total compensation of Mr Novack at Dynavax Technologies is 799,198$. There are 1 executives at Dynavax Technologies getting paid more, with Ryan Spencer having the highest compensation of 859,990$.

How old is Mr Novack?

Mr Novack is 59, he's been the Pres & COO of Dynavax Technologies since . There are 2 older and 3 younger executives at Dynavax Technologies. The oldest executive at Dynavax Technologies Corp. is Michael S. Ostrach, 69, who is the Advisor.

What's Mr Novack's mailing address?

David's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES, 2100 POWELL STREET, SUITE 720, EMERYVILLE, CA, 94608.

Insiders trading at Dynavax Technologies

Over the last 21 years, insiders at Dynavax Technologies have traded over 196,839,440$ worth of Dynavax Technologies stock and bought 2,463,112 units worth 11,318,051$ . The most active insiders traders include Andrew A. F. Hack、Partners L P/Ilbiotechnolog...、James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of 1,533,390$. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth 43,127$.

What does Dynavax Technologies do?

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.

Complete history of Mr Novack stock trades at Dynavax Technologies

Dynavax Technologies executives and stock owners

Dynavax Technologies executives and other stock owners filed with the SEC include:

• Ryan Spencer,
  CEO & Director
• David F. Novack,
  Pres & COO
• Dr. Robert Janssen,
  Chief Medical Officer and Sr. VP of Clinical Devel., Medical & Regulatory Affairs
• Michael S. Ostrach,
  Advisor
• John Slebir,
  Sr. VP & Gen. Counsel
• Nicole Arndt,
  Sr. Mang. of Investor Relations
• Meg Smith,
  VP Sales & Operations
• Steven N. Gersten,
  Chief Ethics & Compliance Officer, Sr. VP, Gen. Counsel and Sec.
• Heather Rowe,
  VP of Investor Relations & Corp. Communications
• Jeff P. Coon,
  Sr. VP of HR & Admin.
• Justin Burgess,
  Principal Accounting Officer & Controller
• Kelly MacDonald,
  Sr. VP & CFO
• Laura Brege,
  Director
• Eddie Gray,
  CEO and Director
• Arnold L Oronsky,
  Director
• Stanley A Plotkin,
  Director
• Daniel L Kisner,
  
• Dennis Carson,
  Director
• Natale S Ricciardi,
  Director
• David Louis Johnson,
  Vice President
• Michael S Ostrach,
  Senior Vice President
• Elaine D Sun,
  
• Francis Cano,
  
• Peter R. Paradiso,
  
• Peggy V Phillips,
  
• Brent Mac Gregor,
  
• Julia Marie Eastland,
  
• Scott Dunseth Myers,
  
• Partners L P/Ilbiotechnolog...,
  
• Nest Gary A Van,
  Vice President
• Dino Dina,
  President and CEO
• Denise Gilbert,
  Director
• Martin E Sanders,
  EVP, Chief Development Officer
• James Edeerfield Capital Lp...,
  
• Partners L P/Ilbiotechnolog...,
  
• James Edeerfield Capital Lp...,
  
• James Edeerfield Capital Lp...,
  
• Deborah A Smeltzer,
  VP Operations & CFO
• Timothy G Henn,
  Vice President
• Zbigniew Janowicz,
  Director
• Daniel Janney,
  Director
• Stephen F Tuck,
  Vice President
• Nancy L Buc,
  Director
• J Tyler Martin,
  VP Clinical Development & CMO
• Christine R Larson,
  VP and Chief Financial Officer
• Capital Partners Lpsymphony...,
  
• Jennifer Lew,
  VP, Finance & PAO
• Mark Kessel,
  Director
• David M Lawrence,
  Director
• Daniel J Levitt,
  VP and Chief Medical Officer
• James Edeerfield Capital Lp...,
  
• Louis C Bock,
  Director
• Jan Leschly,
  Director
• James E Flynn,
  10% owner
• Danielalta California Partn...,
  
• Robert Coffman,
  VP & Chief Scientific Officer
• David F Novack,
  President & COO
• Ryan Spencer,
  CEO and Director
• Robert Janssen,
  SVP and CMO
• Kelly Mac Donald,
  SVP and CFO
• Justin Burgess,
  VP Finance & CAO
• Andrew A. F. Hack,